Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00850382
Recruitment Status : Completed
First Posted : February 25, 2009
Last Update Posted : March 1, 2016
Information provided by (Responsible Party):
Prof. Dr. Hartmut Doehner, University of Ulm